Use of a Viral Filter to Reduce Exposure to Exhaled Aerosol Does Not Affect Methacholine Dose Delivery During Bronchoprovocation Testing

被引:0
|
作者
Subat, Yosuf W. [1 ]
Meyer, Todd J. [2 ]
Torgerud, Keith D. [3 ]
Lim, Kaiser G. [1 ]
Scanlon, Paul D. [1 ]
Niven, Alexander S. [1 ]
机构
[1] Mayo Clin, Dept Med, Div Pulm Crit Care & Sleep Med, Rochester, MN 55905 USA
[2] Mayo Clin, Resp Care, Rochester, MN 55905 USA
[3] Mayo Clin, Resp Care & Cardiopulm Diagnost, La Crosse, WI USA
关键词
methacholine; aerosol; asthma; COVID-19; SARS-CoV-2; infection control; ASTHMA;
D O I
10.4187/respcare.09703
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
BACKGROUND: Methacholine challenge testing (MCT) is a common bronchoprovocation technique used to assess airway hyper-responsiveness. We previously demonstrated that the addition of a viral filter to the nebulizer exhalation limb substantially reduced expelled particles during MCT. Our aim was to evaluate whether this modification affects the delivered dose of methacholine. METHODS: A mechanical ventilator was connected to a lung simulator with breathing frequency 15 breaths/min, tidal volume 500 mL, inspiratory-expiratory ratio 1:1, with a sinusoidal waveform. We compared methacholine dose delivery using the Hudson Micro Mist or AeroEclipse II BAN nebulizers powered by either a dry gas source or a compressor system. A filter placed in line between the nebulizer and test lung was weighed before and after 1 min of nebulized methacholine delivery. Mean inhaled mass was measured with and without a viral filter on the exhalation limb. Dose delivery was calculated by multiplying the mean inhaled mass by the respirable fraction (particles < 5 mu m) and inhalation time. Unpaired t test was used to compare methacholine dose delivery with and without viral filter placement. RESULTS: The addition of a viral filter did not significantly affect methacholine dose delivery across all devices tested. Using a 50-psi dry gas source, dose delivered with or without a viral filter did not differ with the Hudson (422.3 mu g vs 282.0 mu g, P = .11) or the AeroEclipse nebulizer (563.0 mu g vs 657.6 mu g, P = .59). Using the compressor, dose delivered with and without a viral filter did not differ with the Hudson (974.0 mu g vs 868.0 mu g, P = .03) or the AeroEclipse nebulizer (818.0 mu g vs 628.5 mu g, P =.42). CONCLUSIONS: The addition of a viral filter to the nebulizer exhalation limb did not affect methacholine dose during bronchoprovocation testing. Routine use of a viral filter should be considered to improve pulmonary function technician safety and infection control measures during the ongoing COVID-19 pandemic.
引用
收藏
页码:899 / 905
页数:7
相关论文
empty
未找到相关数据